Royalty Pharma Plc- Cl A

CEVA shares tumbled 16% after Q2 results showed a licensing surge but royalty growth of only 1%, as AI design wins have yet to generate production revenue.

Ouster shares surged 17% in premarket trading following a surprise quarterly profit, largely fueled by a significant one-time royalty payment. The company's Q4 revenue reached $62.2 million with GAAP net income of $4 million.